Design and application of locally delivered agonists of the adenosine A2A receptor

Expert Review of Clinical Pharmacology

Volumn 3, Issue 1, 2010, Pages 55-72

  Mantell, Simon ^a   Jones, Rhys ^a   Trevethick, Mike ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Acute lung injury; Adenosine A2A receptor; Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease; Glaucoma; Inflammation; Lung retention; Tissue retention; Topical administration; Wound healing

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; APADENOSON; ATL 313; CAFFEINE; CORTICOSTEROID; GW 328267X; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; SONEDENOSON; UK 432097; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTIFICIAL VENTILATION; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLITIS; COUGHING; CROHN DISEASE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG EXPOSURE; DRUG PENETRATION; DRUG POTENCY; DRUG RETENTION; DRUG SELECTIVITY; DRUG STRUCTURE; ENTERITIS; GLAUCOMA; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; REVIEW; TUMOR REGRESSION; ULCERATIVE COLITIS; WOUND HEALING;

EID: 77949716625     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.57     Document Type: Review

References (135)

1. Fredholm BB, Ijzerman AP, Jacobson KA et al. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53, 527-552 (2001).
2. Fredholm BB, Arslan G, Halldner L et al. Structure and function of adenosine receptors and their genes. Naunyn- Schmiedeberg's Arch Pharmacol. 362, 364-374 (2000).
3. Yegutkin GG. Nucleotide and nucleoside converting ectoenzymes: important regulators of purinergic signalling cascade. Biochim. Biophys. Acta 1783, 673-694 (2008).
4. Hasko G, Linden J, Cronstein B et al. Adenosine receptors therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 7, 759-770 (2008).
5. Hasko G, Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J. Leuk. Biol. 83, 447-455 (2008).
6. Jacobsen KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Disc. 5, 247-264 (2006).
7. Trevethick MA, Mantell SJ, Stuart EF et al. Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions. Br. J. Pharmacol. 155. 463-474 (2008).
8. Linden J. Adenosine in tissue protection and tissue regeneration. Mol. Pharmacol. 67, 1385-1387 (2005).
9. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 14, 1351-11323 (2007).
10. Gessi S, Varani K, Merighi S et al. A2A adenosine receptors in human peripheral blood cells. Br. J. Pharmacol. 129, 2-11 (2000).
11. Duffy SM, Cruse G, Brighting CE et al. Adenosine closes the K+ channel Kca3.1 in human lung mast cells and inhibits their migration via the adenosine A2A receptor. Eur. J. Immunol. 37, 1653-1662 (2007).
12. Sands WA, Martin AF, Strong EW et al. Specific inhibition of nuclear factor kB dependent inflammatory responses by cell type specific mechanisms upon A2A adenosine receptor gene transfer. Mol. Pharmacol. 66, 1147-1159 (2004).
13. Sands WA, Palmer TM. Regulating gene transcription in response to cyclic AMP elevation. Cell. Signal. 20, 460-466 (2008).
14. Majamdar S, Aggarwal BB. Adenosine suppresses activation of nuclear factor kB selectively by tumour necrosis in different cell types. Oncogene 22, 1206-1218 (2003).
15. Sands WA, Woolson HD, Milne GR et al. exchange protein activated by cyclic AMP [Epac]-mediated induction of suppressor of cytokine signalling 3 (SOCS 3) in vascular endothelial cells. Mol.Cell Biol. 26, 6333-6346 (2006).
16. Kreckler LM, Gizewski E, Wan TC et al. Adenosine suppresses LPS-induced TNF-{a} production by murine macrophages through a protein kinase A- and Epac-independent signaling pathway J. Pharmacol. Exp. Ther. 331(3), 1051-1061 (2009).
17. Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen activated protrein kinases. Cell Signal. 15, 813-827 (2003).
18. Peyssonnaux C, Datta V, Cramer T et al. HIF-1 expression regulates the bactericidal capacity of phagocytes. J. Clin. Invest. 115, 1806-1815 (2005).
19. De Ponti C, Carini R, Alchera E et al. Adenosine A2A receptor mediated normoxic induction of HIF-1 through PKC and PI-3K dependent pathways in macrophages. J. Leuk. Biol. 82, 392-402 (2007).
20. Vivier E, Tomasello E, Baratin M et al. Functions of natural killer cells. Nature Immunol. 9, 503-510 (2008).
21. Yamamura T, Sakuishi K, Illes Z et al. Understanding the behaviour of invariant NKT cells in autoimmune diseases. J. Neuroimmunol. 191, 8-15 (2007).
22. Lappas CM, Day YJ, Marshall MA et al. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J. Exp. Med. 203, 2369-2648 (2006).
23. Meyer EH, DeKruyff RH, Umetsu DT. T cells and NKT cells in the pathogenesis of asthma. Ann. Rev. Med. 59, 1174-1181 (2008).
24. Ueeda M, Thompson RD, Arroya LH et al. 2-aralkoxyadenosines:potent and selective agonists at the coronary artery A2 adenosine receptor. J. Med. Chem. 34, 1340-1344 (1991).
25. LaLanne M, Andrieux K, Couvreur P. Strategies to increase oral bioavailability of nucleoside analogs. Curr. Med. Chem. 16, 1391-1399 (2009).
26. Tayab ZR, Hochus G. Pharmacokinetic- pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. Expert Opin. Drug Deliv. 2, 519-532 (2005).
27. Edsbaecker S, Brattsand R. Budesonide fatty acid esterification: a novel mechanism prolonging binding to airway tissue. Ann. Allergy Asthma Immunol. 6, 608-616 (2002).
28. Lipinski CA, Lombardo F, Dominy BW et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv. Drug. Deliv. Revs. 46, 3-26 (2001).
29. Mantell SJ, Stephenson PT, Monaghan SM et al. SAR of a series of inhaled A2A agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data. Bioorg. Med. Chem. Lett. 19, 4471-4475 (2009).
30. Wu K, Blomgren AL, Ekholm K et al. Budesonide and ciclesonide: effect of tissue binding on pulmonary receptor binding. Drug Metab. Disposition 37, 1421-1426 (2009).
31. Szczuka A, Wennerberg M, Packeu A et al. Molecular mechanisms for the persistent bronchodilatory effect of the b2 adrenoceptor agonist salmeterol. Br. J. Pharmacol. 158, 183-194 (2009).
32. Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced affinity glucocorticoid, fluticasone furoate. Resp. Res. 8, 1-9 (2007).
33. Kwon Y. Pharmacodynamics and drug metabolism for industrial scientists. In: Handbook of Essential Pharmacokinetics. Kluwer Academic/Plenum Press, NY, USA 25-26 (2002).
34. Hutchison AJ, Williams M, De Jesus R et al. 2-(arylalkylamino)adenosin- 5́- uronamides: a new class of highly selective adenosine A2 receptor ligands. J. Med. Chem. 33, 1919-1924 (1990).
35. Bridges A.J, Moos, WH, Szotek DL et al. N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity. J. Med. Chem. 30, 1709-1711 (1987).
36. Bevan N, Butchers PR, Cousins R et al. Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6- amino-2-{[(1S)-2-hydroxy-1- (phenylmethyl)ethyl]amino}-9H-purin-9- yl)-5-(2-ethyl-2H-tetrazol-5-yl) tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A2A receptor agonist and adenosine A3 receptor antagonist activity. Eur. J. Pharmacol. 564, 219-225 (2007).
37. Trevethick MA, Salmon G, Banner K et al. UK-432,097 a novel potent adenosine A2A receptor agonist; comparison of the in vitro anti-inflammatory properties with the phosphodiestearse inhibitor Ariflo. Proceedings of the American Thoracic Society A73 (2005).
38. Wang J, Krudy G, Hou T et al. Development of reliable aqueous solubility models and their application in drug like analysis. J. Chem. Inf. Model. 47, 1395-1404 (2007).
39. Jain N, Yalkowsky S. Estimation of aqueous solubility 1: application to organic nonelectrolytes. J. Pharm. Sci. 90, 234-250 (2001).
40. Tolman JA, Williams RO. Advances in the pulmonary delivery of poorly soluble drugs:influence of solubilisation on pharmacokinetic properties. Drug Dev. Ind. Pharm. DOI: 10.1080/03639040903092319 (2009) (Epub ahead of print).
41. Greiner AN. Allergic rhinitis: impact of the disease and considerations for management. Med. Clin. N. Am. 90, 17-38 (2006).
42. Matera MG, Polosa R. Adenosine receptors: novel targets for drug development in allergic rhinitis. Clin. Exp. Allergy 37, 4-7 (2007).
43. El-Hashim AZ, Abduo HT, Rachid OM et al. Intranasal administration of NECA can induce anti-inflammatory and proinflammatory effects in BALB/c mice: evidence for A2A receptor subtype mediation of NECA-induced anti-inflammatory effects. Pulm. Pharmacol. Ther. 30, 1-10 (2009).
44. Rimmer J, Peake HL, Santos CMC et al. Targeting adenosine receptors in the treatment of allergic rhinitis: a randomised double-blind placebocontrolled study. Clin. Exp. Allergy 37, 8-14 (2007).
45. Constantino HR, Illum L, Brandt G et al. Intranasal delivery: physicochemical and therapeutic aspects Int. J. Pharmaceutics 337, 1-24 (2007).
46. Martin E, Schipper NGM, Verhoef JC et al. Nasal mucocilliary clearance as a factor in nasal drug delivery. Adv. Drug Deliv. Rev. 29, 13-38 (1998).
47. Mantell SJ, Stephenson PT, Monaghan SM et al. Inhaled adenosine A2A receptor agonists for the treatment of chronic obstructive pulmonary disease. Bioorg. Med. Chem. Lett. 18, 1284-1287 (2008).
48. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov. Today 7, 967-975 (2002).
49. Illum L. Nasal clearance in health and disease. J. Aerosol. Med. 19, 92-99 (2006).
50. Ichinose M. Differences of inflammatory mechanisms in asthma and COPD. Allergol Int. 58, 307-313 (2009).
51. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 8, 183-192 (2008).
52. Fanta CH. Asthma. N. Eng. J. Med. 360, 1002-1014 (2009).
53. Wilson CN. Adenosine receptors and asthma in humans. Br. J. Pharmacol. 155, 475-486 (2008).
54. Zhou Y, Schneider DJ, Blackburn MR. Adenosine signaling and the regulation of chronic lung disease. Pharmacol Ther.123, 105-116 (2009).
55. Weeda M, Zanen P, de Boer AH et al. The therapeutic index of locally acting inhaled drugs as a function of their fine particle mass and particle size distribution - a literature review. Curr. Drug. Deliv. 5, 142-147 (2008).
56. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br. J. Clin. Pharmacol. 42, 697-705 (1996).
57. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J. Clin. Pharmacol. 47, 782-789 (2007).
58. Hofmann W, Asgharian B. The effect of lung structure on mucociliary clearance and particle retention in human and rat lungs. Toxicol. Sci. 73, 448-456 (2003).
59. Glover W, Chan H, Eberl S et al. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int. J. Pharmaceutics. 349, 314-322 (2008).
60. Luijk B, van den Berge M, Kerstjens HAM et al. Effect of an inhaled adenosine A2A agonist on the allergen-induced late asthmatic response. Allergy 63, 75-80 (2008).
61. Webb RL, Sills MA, Chovan JP et al. Development of tolerance to the antihypertensive effects of highly selective adenosine A2A agonists upon chronic administration. J. Pharmacol. Ex.p Ther. 267, 287-295 (1993).
62. Adami M, Bertorelli R, Ferri N et al. Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole- induced convulsions in the rat. Eur. J. Pharmacol. 294, 383-399 (1995).
63. Zezula J, Freissmuth M. The A2A adenosine receptor: a GPCR with unique features? Br. J. Pharmacol. 153(Suppl. 1), S184-S190 (2008).
64. Seemungal T, Sykes A; the ICEAD Contributors. Recent advances in exacerbations of COPD. Thorax 63, 850-852 (2008).
65. Pallan S, Mahoney JB, O'Byrne PM et al. Asthma management by monitoring sputum neutrophil count. Chest 134, 628-630 (2008).
66. Schepp CP, Reutershan J. Bench to bedside review: adenosine receptors - promising targets in acute lung injury. Crit. Care 12, 1-8 (2008).
67. Abraham A. Neutrophils and acute lung injury. Crit. Care. Med. 31(Suppl.), S195-S199 (2003).
68. Yang KY, Arcaroli JJ, Abraham E. Early alterations in neutrophil activation are associated with outcome in acute lung injury. Am. J. Resp. Crit Care Med. 167, 1567-1574 (2003).
69. Thiel M, Chouker A, Ohta A et al. Oxygenation inhibits the physiological tissue protection mechanism and thereby exacerbates acute inflammatory lung injury. PloS Biol. 3, 1008-1100 (2005).
70. Sitkovsky MV, Ohta A. The danger sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol. 26, 299-304 (2005).
71. Eckle T, Grenz A, Laucher S et al. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J. Clin. Invest. 118, 3301-3315 (2008)
72. Chen CM, Penuelas O, Quinn K et al. Protective effects of adenosine A2A receptor agonist in ventilator-induced lung injury in rats. Crit. Care Med. 37, 2235-2241 (2009).
73. Dhand R. Inhalation therapy with metered dose inhalers and dry powder inhalers in mechanically ventilated patients. Respiratory Care. 50, 1331-1344 (2005).
74. Cohen S, Khatana AK, Greff LJ. Evolving paradigms in the medical management of glaucoma. Int. Ophthalmol. 25, 253-265 (2004).
75. Tamm ER, Ethier CR. Current aspects of aqueous humor dynamics and glaucoma. Exp. Eye Res. 88, 618-619 (2009).
76. Grieshaber MC, Flammer J. Blood flow in glaucoma. Curr. Opin. Ophthalmol. 16, 79-83 (2005).
77. Leske MC. Ocular perfusion pressure and glaucoma: clinical trial and epidemiologic findings. Curr. Opin. Ophthalmol. 20, 73-78 (2009).
78. Daines BS, Kent AR, Mcaleer MS et al. Intraoccular adenosine levels in normal and occular hypertensive patients. J. Ocular Pharmacol. Ther. 19, 113-120 (2003).
79. Macaluso C, Frishman LJ, Frueh B et al. Multiple effects of adenosine in the arterially perfused mammalian eye. Possible mechanisms for the nueroprotective function of adenosine in the retina. Documenta Ophthalmologica 106, 51-59 (2003).
80. Polska P, Ehrlich P, Luksch A et al. Effects of adenosine on intraocular pressure, optic head blood flow and choroid blood flow in healthy humans. Invest. Ophthalmol. Vis. Sci. 44, 3110-3114 (2003).
81. Konno T, Uchibori T, Nagai A et al. Effect of 2-(6-cyano-1-hexyn-1-yl) adenosine on ocular blood flow in rabbits. Life Sci. 80, 1115-1122 (2007).
82. Hein TW, Yuan Z, Rosa RH Jr et al. Requisite roles of A2A receptors, nitric oxide, and KATP channels in retinal arteriolar dilation in response to adenosine. Invest. Ophthalmol. Vis. Sci. 46, 2113-2119 (2005).
83. Wax MB, Tezel G. Immunoregulation of retinal ganglion cell: fate in glaucoma. Exp. Eye. Res. 88, 825-830 (2009).
84. Liou GI, Auchampach JA, Hillard CJ et al. Mediation of cannabidiol antiinflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Invest. Ophthalmol. Vis. Sci. 49, 5526-5531 (2008).
85. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc. Natl Acad. Sci. USA 103, 7895-7900 (2006).
86. Shirasaki Y. Molecular design for enhancement of ocular penetration. J. Pharmacol. Sci. 97, 2462-2496 (2008).
87. Crosson CE, Grat T. Characterisation of ocular hypertension induced by adenosine agonists. Invest. Ophthalmol. 37, 1833-1839 (1996).
88. Konno T, Murakami A, Uchibori T et al. Involvement of adenosine A2A receptor in intraocular pressure decrease induced by 2-(1-octyn-1-yl)adenosine or 2-(6-cyano-1- hexyn-1-yl)adenosine. J. Pharmacol. Sci. 97, 501-519 (2005).
89. Konno T, Sato A, Uchibori T et al. Adenosine A2A receptor mediated protective effect of 2-(6-cyano-1-hexyn-1- yl)adenosine on retinal ischaemia/ reperfusion damage in rats. Br. J. Ophthalmol. 90, 900-905 (2006).
90. Konno T, Ohnuma SY, Uemoto K et al. Effects of 2-alkynyladenosine derivatives on intraocular pressure in rabbits. Eur. J. Pharmacol. 486, 307-316 (2004).
91. Avila MY, Stone RA, Civan MM. A1, A2A and A3 subtype adenosine receptors modulate intraocular pressure in the mouse. Br. J. Pharmacol. 134, 241-245. (2001).
92. Cronstein BN, Levin RI, Philips M Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J. Immunol. 148, 2201-2206 (1992).
93. Lawrence MS, Miller JW. Ocular tissue permeabilities. Int. Ophthalmol. Clin. 44, 53-61(2004).
94. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 366, 1736-1743 (2005).
95. Vallis MD, Cronstein BN, Montesinos MC. Adenosine receptor agonists for the promotion of dermal wound healing. Biochem. Pharmacol. 77, 1117-1124 (2009).
96. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615-1624 (2005).
97. Montesinos MC, Gadangi P, Longaker M et al. Wound healing is accelerated by agonists of adenosine A2 (G a s-linked) receptors. J. Exp. Med. 186, 1615-1620 (1997).
98. Chan ES, Fernandez P, Merchant AA et al. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 54, 2632-2642 (2006).
99. Montesinos MC, Shaw JP, Yee H et al. Adenosine A2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am. J. Pathol. 164, 1887-1892 (2004).
100. Desai A, Victor-Vega C, Gadangi S et al. Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. Mol. Pharmacol. 67, 1406-1413 (2005).
101. Hasday JD, Sitrin RG. Adenosine receptors on rabbit alveolar macrophages: binding characteristics and effects on cellular function. J. Lab. Clin. Med. 110, 264-273 (1987).
102. Cronstein BN. Adenosine receptors and wound healing. Scientific World 4, 1-8 (2004).
103. Victor-Vega C, Desai A, Montesinos MC et al. Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel). Inflammation 26, 20-24 (2002).
104. Montesinos MC, Desai A, Chen JF et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A2A receptors Am. J. Pathol. 160, 2009-2018 (2002).
105. Peirce SM, Skalak T, Reiger JM et al. Selective A2A adenosine receptor activation reduces skin pressure formation and inflammation. Am. J. Physiol. Heart Circ. Physiol. 281, H67-H74 (2001).
106. Bamias G, Cominelli F. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr. Opin.Gastroenterol. 23, 365-369 (2007).
107. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117, 54-521 (2007).
108. Ye JH, Rajendran VM. Adenosine: an immune modulator of inflammatory bowel disease. World J. Gastroenterol. 15, 4491-4498 (2009).
109. Antonioli L, Fornai M, Colucci R et al. Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J. Pharmacol. Exp. Ther. 322, 435-442 (2007).
110. Siegmund B, Rieder F, Albrich S et al. Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J. Pharmacol. Exp. Ther. 296, 99-105 (2001).
111. Odashima M, Bamias G, Rivera-Nieves J et al. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 129, 26-33 (2005).
112. Cavalcante IC, Castro MV, Barreto AR et al. Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect. Immun. 74, 2606-2612 (2006).
113. Naganuma M, Wiznerowicz EB, Lappas CM et al. Cutting Edge: critical role for A2A adenosine receptors in the T cell mediated regulation of colitis. J. Immunol. 177, 2765-2769 (2006).
114. Koizumi S, Odashima M, Otaka M et al. Attenuation of gastric mucosal inflammation induced by indomethacin through activation of the adenosine receptor in rats. J. Gastroenterol. 44, 419-425 (2009).
115. Koizumi S, Odashima M, Otaka M et al . Attenuation of gastric mucosa inflammation induced by indomethacin through activation of the A2A adenosine receptor in rats. J. Gastroenterol. 44, 419-425 (2009).
116. Seow CH, Benchimol EI, Steinhart AH et al. Budesonide for Crohn's disease. Expert Opin. Drug Metab. Toxicol. 5, 971-979 (2009).
117. Kesisoglou F, Zimmermann EM. Novel drug delivery strategies for the treatment of inflammatory bowel disease. Expert Opin. Drug Deliv. 2, 451-463 (2005).
118. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44, 235-249 (2000).
119. Sitkovsky MV, Kjaergaard J, Lukashev D et al. Hypoxia-adenosinergic immunosuppression: tumour protection by T regulatory cells and cancerous tissue hypoxia. Clin. Cancer. Res. 14, 5947-5952 (2008).
120. Harlin H, Kuna TV, Peterson AC et al. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol. Immunother. 55, 1185-1197 (2006).
121. Sitkovsky M. T regulatory cells: hypoxiaadenosinergic suppression and re direction of the immune response. Cell 30, 102-108 (2009).
122. Lukashev D, Sitkovsky M, Ohta A. From Hellstrom paradox to anti-adenosinergic cancer immunotherapy. Purinergic Signal. 3, 129-134 (2007).
123. Ohta A, Gorelik E, Prasad SJ. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl Acad. Sci. USA 103, 13132-13137 (2006).
124. Nkondjock A. Coffee consumption and the risk of cancer: an overview. Cancer Letts. 277, 121-125 (2009)
125. Hoskin DW, Mader JS, Furlong SJ et al. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumour cells. Int. J. Oncol. 32, 527-535 (2008).
126. Fishman P, Bar-Yehuda S, Synowitz M et al. Adenosine receptors and cancer. Handb. Exp. Pharmacol. 193, 399-441 (2009).
127. Sitkovsky M, Lukashev D, Deaglio S et al. Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br. J. Pharmacol. 153(Suppl. 1), S457-S464 (2008).
128. Ohta A, Kjaergaard J, Sharma S et al. In vitro induction of T cells that are resistant to A2 adenosine receptormediated immunosuppression. Br. J. Pharmacol. 156, 297-306 (2009).
129. Compounds useful as agonists of A2A adenosine receptors, cosmetic composition with A2A agonists and a method for using the same. US 2007/0183995 A1 Aug 9 (2007).
130. Adcock JJ. TRPV1 receptors in sensitisation of cough and pain reflexes. Pulm. Pharmacol. Ther. 22, 65-70 (2009).
131. Puntambekar P, Van Buren J, Raisinghani M et al. Direct interaction of adenosine with the TRPV1 channel protein. J. Neurosci. 24, 3663-3671 (2004).
132. Alam MS, Kurtz C, Wilson JM et al. A2A adenosine receptor activation inhibits proinflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. Mucosal Immunol. 2, 232-242 (2009).
133. Fernández P, Trzaska S, Wilder T et al. Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine. Am. J. Pathol. 172, 1675-1682 (2008).
134. Chan ES, Montesinos MC, Fernandez P et al. Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis. Br. J. Pharmacol. 148, 1144-1155. (2006).
135. Banker MJ, Clark TH, Williams JA. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J. Pharm. Sci. 92, 967-974 (2003).